FIELD: medicine.
SUBSTANCE: method involves adding Verapamil and Genistein as ABC-transport activity inhibitors to patient tumor cells suspension in two different concentrations and sodium azide and the samples are incubated. Then, Doxorubicin is added in two different concentrations and incubated once more. Next, formalin is added and fluorescence values are determined in each sample Relative intracellular Doxorubicin fluorescence variation after having treated the samples with each of applied inhibitors in concentrations of interest and each Doxorubicin concentration under study. The received data are interpreted to draw conclusions concerning individual tumor sensitivity to chemotherapy with cytostatic agents of multiple drug resistance.
EFFECT: accelerated high accuracy study.
3 cl, 10 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD OF IMMUNOFLUORESCENT ANALYSIS OF MARKERS OF MULTIPLE MEDICATION RESISTANCE IN HUMAN SOLID TUMOURS | 2009 |
|
RU2413948C1 |
| METHOD OF TREATING BREAST CANCER BY DETERMINING INDIVIDUAL SENSITIVITY TO CHEMOTHERAPY BY CULTURE TECHNIQUE AND USE OF COMBINATION OF HERBAL CYTOSTATICS | 2011 |
|
RU2470658C1 |
| METHOD FOR PERSONALIZED ASSIGNMENT OF NEOAJUVANT CHEMOTHERAPY TO PATIENTS SUFFERING FROM LUMINAL TYPE B BREAST CANCER | 2015 |
|
RU2594251C1 |
| ANTITUMOR COMPOSITION OF DOXORUBICIN WITH ATP INHIBITOR-DEPENDENT REVERSE CELL TRANSPORTER | 2018 |
|
RU2680834C1 |
| PREPARATION FOR OVERCOMING MULTIDRUG RESISTANCE | 2008 |
|
RU2434879C2 |
| AGENT INHIBITING MULTIPLE DRUG RESISTANCE OF TUMOUR CELLS | 2012 |
|
RU2494742C1 |
| ANTI-TUMOUR PREPARATION | 2011 |
|
RU2451509C1 |
| OSTEOGENIC HUMAN SARCOMA CELL LINE 793 OSSAR RVV | 2019 |
|
RU2722867C1 |
| CONJUGATE POSSESSING SELECTIVE EFFECT WITH RESPECT TO CANCER TUMORS | 2005 |
|
RU2303997C2 |
| POLYMER CONTAINING MEDICINAL AGENT BASED ON ANTITUMOR AGENT ETOPOSIDE | 2015 |
|
RU2595859C1 |
